| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | GSK2126458 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.0049 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |